BRAF and colorectal carcinoma: We used the BRAF and KRAS wildtype CaCO2 colorectal carcinoma cell line, harboring Doxycycline inducible constructs expressing BRAFV600E and KRASG12V as well as cell lines with naturally occurring BRAFV600E (HT29) and KRASG12V (SW480) mutations.